Scanning electron microscopy of multidrug resistant cells in haematological and mammary malignancies.
Multidrug resistance (MDR) is frequently found in haematologic malignancies. It has been shown that MDR is often related to the expression of a membrane glycoprotein (P-170) which actively pumps many hydrophobic agents out of the cells. Previous electron microscopic investigations revealed morphological differences between P-388 resistant and P-388 sensible cell membranes, but the modulation of the membrane morphology seems to be related to the tumor-cell environment. In order to establish if morphological differences exist between sensitive and resistant cells, both sensitive and resistant strains from three different cell lines were studied by scanning electron microscopy: human leukaemia CEM and vinblastine resistant cells (CEM/VBL100), human breast cancer MCF-7 and mice leukaemia P-388 with the doxorubicin resistant strains (MCF-7/DX and P-388/DX, respectively). The surface of the membranes of the sensitive cells was regular, unlike the resistant ones which proved to be irregular, endowed with long villus-like processes or numerous folds and ruffles. The addition of albumin to the culture medium induced a shift from the resistant to the sensitive phenotype, thus suggesting that the P-388/DX morphology may be linked to the concentration of protein in the culture medium. Exposure to DX, verapamil (VRP) or monoclonal antibody against P-170 (mAb-57) did not modify the surface of the resistant strains, demonstrating that surface irregularities are probably not linked to P-glycoprotein function. Blasts from four P-170 positive leukaemic patients were also analyzed: an irregular shape was always found.
Galimberti
S
S
Scuola Superiore di Studi e di Perfezionamento, Pisa, Italy.
Bianchi
F
F
Bernardini
N
N
Mattii
L
L
Dolfi
A
A
Lupetti
M
M
Petrini
M
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000208:Acute Disease; D000818:Animals; D001752:Blast Crisis / Q000473:pathology; D001943:Breast Neoplasms; D002352:Carrier Proteins / Q000032:analysis / Q000096:biosynthesis*; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004317:Doxorubicin / Q000633:toxicity*; D004351:Drug Resistance; D005260:Female; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000473:pathology*; D007941:Leukemia P388; D007945:Leukemia, Lymphoid; D008562:Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis*; D051379:Mice; D008855:Microscopy, Electron, Scanning; D012333:RNA, Messenger / Q000032:analysis; D013936:Thymidine / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology; D014747:Vinblastine / Q000633:toxicity*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002352:Carrier Proteins; D004273:DNA, Neoplasm; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D014747:Vinblastine; D004317:Doxorubicin; D014700:Verapamil; D013936:Thymidine